PEMF for Knee
Osteoarthritis.

May 2026 · 9 min read · Clinical Protocol

The Knee OA Burden — and Why the Philippines Is a High-Priority Market

Osteoarthritis of the knee (knee OA) is the most prevalent form of arthritis worldwide, affecting an estimated 14% of adults over 45 and 34% of those over 65. In the Philippines, with a population of over 110 million and one of Southeast Asia's fastest-aging demographics, knee OA represents the single highest-volume diagnosis presenting to orthopaedic and physiotherapy clinics. Most patients face a stark treatment landscape: NSAIDs with GI and cardiovascular risk, expensive hyaluronic acid injections that require repeat courses every 6–12 months, or eventual total knee replacement — the third most common inpatient surgical procedure in the country.

PEMF occupies a compelling position in this landscape: it addresses the pathophysiology of cartilage degradation and synovial inflammation directly, is non-invasive, requires no pharmacological exposure, and has been studied in more randomized controlled trials than any other PEMF indication. ⚠️ The evidence is genuinely mixed rather than uniformly positive, and this page reports both halves of it below.

How PEMF Works on Knee Cartilage and Synovium

Knee OA involves four parallel degradative processes, and PEMF has been shown to act on each of them in laboratory work. ⚠️ Everything in the list below is derived from cell-culture and animal studies — it explains why PEMF might work, not that it does. The human evidence, including what it failed to show, is in the next section.

1. Chondrocyte stimulation and matrix synthesis — PEMF activates chondrocytes via adenosine-A2A receptor signaling, upregulating type II collagen and aggrecan synthesis. In cartilage explant studies, PEMF exposure increases proteoglycan content by 20–35% compared to unexposed controls.
2. IL-1β and TNF-α suppression — these are the primary pro-inflammatory cytokines driving cartilage matrix metalloproteinase (MMP) activity. PEMF reduces both by 40–60% at the synovial level in OA models, slowing the catabolic cascade.
3. Subchondral bone remodeling — PEMF promotes osteoblast activity and improves subchondral bone density, addressing the bone-cartilage interface that is increasingly recognized as the primary source of OA pain.
4. Synovial fluid viscosity and production — electromagnetic stimulation improves synoviocyte function, normalizing hyaluronic acid production and reducing joint friction.

A magnetic field is not attenuated by skin, fat or bone in the way that ultrasound or a topical agent is, which is the practical basis for treating a deep joint through clothing without contact. ⚠️ Penetration figures quoted in marketing material vary widely between device classes and are rarely traceable to a measurement protocol; treat any specific centimetre figure as a manufacturer specification for one model rather than a property of the technology.

The Meta-Analysis Evidence: 11 RCTs, 614 Patients

The systematic review and meta-analysis by Tong et al. (PubMed 35586276, PMC9110240, Pain Research and Management, 2022) pooled 11 randomized controlled trials enrolling 614 OA patients, of which 10 trials were knee-specific and one included hand OA. Outcomes versus control:

• Pain: SMD = 0.71 (95% CI: 0.08–1.34; p = 0.03) — medium-to-large effect
• Stiffness: SMD = 1.34 (95% CI: 0.45–2.23; p = 0.003) — large effect
• Physical function: SMD = 1.52 (95% CI: 0.49–2.55; p = 0.004) — very large effect

An SMD of 1.52 on physical function is a large pooled effect. ⚠️ Two caveats belong with it: the confidence interval is wide (0.49–2.55), which reflects heterogeneity across a small number of trials, and effect sizes from separate literatures cannot be lined up against each other — comparing this figure to a reported effect size for total knee replacement is not a valid comparison and is not made here. PEMF is not an alternative to arthroplasty in a knee that needs one.

The pooled result above is the optimistic end of the evidence, and two more recent papers pull it back. Both are reported here in full, because a protocol built on the favourable half of the literature does not survive contact with an informed patient.

The 2026 double-blind, placebo-controlled RCT (Lau et al., Journal of Cachexia, Sarcopenia and Muscle, PubMed 41588476, n=60, NCT05442697) randomised refractory mild-to-moderate knee OA patients to PEMF or SHAM, 30 minutes 3×/week for 8 weeks, with follow-up to 12 months. What it found: knee extensor strength rose 72% from baseline versus 25% in the sham group at 6 months (p=0.003), and extension peak torque was significantly greater than sham (p=0.042). 🚨 What it did not find, and this is the part that must be quoted to patients: no difference between PEMF and sham in lean muscle mass, femoral cartilage thickness, minimum joint space width, 6-metre walk time, 30-second chair stands, or WOMAC — at any timepoint through 12 months (all p>0.05).

The 2026 systematic review and meta-analysis (Chang, Lin & Huang, Medicina (Kaunas), PubMed 42075549, 9 RCTs, n=457) found no significant improvement in VAS pain or total WOMAC at one month. WOMAC-pain improved significantly at 18–21 days but not at one month; stiffness and daily activity improved only at one month; objective functional measures did not improve; and overall risk of bias across the included trials was high. The authors' own conclusion is that although the improvements are statistically significant, "these improvements may not reach thresholds for clinical meaningfulness."

How to hold both results at once. The honest reading is that PEMF has a real but moderate analgesic and functional effect in knee OA, a documented effect on quadriceps strength, and no demonstrated effect on cartilage structure in humans. That is a defensible clinical position. "PEMF rebuilds cartilage" is not.

Clinical Protocol

PEMF vs. Standard Knee OA Interventions

Integrating PEMF with Physiotherapy and Graded Exercise

The highest-evidence combination for knee OA is PEMF + progressive resistance training + proprioceptive exercise. The sequencing that delivers best outcomes in Israel's 70+ Israeli clinics (population: 9M) — now expanding to the Philippines:

• PEMF session: reduces intra-articular inflammation and pain threshold — the patient arrives capable of exercising
• Same-day physiotherapy: quadriceps strengthening, proprioceptive training, gait retraining — more effective when PEMF has pre-treated the joint
• Home exercise program: sustains gains between clinic sessions; PEMF-treated patients show higher exercise adherence due to reduced post-exercise soreness

A 2024 RCT (Journals of SAGE) confirmed that PEMF + progressive resistance exercise produced significantly greater WOMAC score improvement than exercise alone, with the combined group showing 2.4× better pain outcomes at 8 weeks.

Grading and Patient Selection

PEMF is appropriate across Kellgren–Lawrence grades I–III (mild to moderate OA). Grade IV patients (bone-on-bone) with surgical candidacy should be assessed individually — PEMF can manage pain and function while patients await surgery, and may delay the need for arthroplasty in Grade III patients by 18–36 months based on clinical series data.

Contraindications

• Active electronic implant near knee (rare for knee OA; pacemaker patients with remote implant sites can typically still be treated)
• Active malignancy in treatment area
• Acute septic arthritis (bacterial infection of joint — treat infection first)
• Recent intra-articular injection: allow 48–72 hours before PEMF to avoid disrupting the hyaluronic acid distribution

FAQ

How does PEMF compare to physiotherapy alone for knee OA?

They are complementary rather than competing, and the order matters. Exercise and load management are the core of every clinical guideline for knee OA, including the 2019 ACR/Arthritis Foundation guideline (PubMed 31908149), in which PEMF does not appear as a recommended treatment. The defensible role for PEMF is the one the 2026 RCT actually documented: reducing pain enough to make the loading programme achievable, and improving extensor strength — the muscle deficit that most directly limits function. A clinic that positions PEMF as a replacement for graded exercise is selling something the evidence does not support.

Does PEMF actually repair cartilage or just reduce pain?

It reduces pain and improves strength. It does not repair cartilage, and the human data on that question is no longer ambiguous. The 2026 double-blind placebo-controlled trial (PubMed 41588476) measured femoral cartilage thickness and minimum joint space width directly, in patients, out to 12 months, and found no difference from sham. The chondrogenic effects reported for type II collagen and proteoglycan synthesis come from cell culture and animal models (for example PubMed 39990654) and have not translated into a measurable structural change in humans. Tell patients this before the first session, not after their follow-up X-ray.

Is knee OA a good first indication for a new PEMF clinic?

Yes — it is the highest-volume, best-evidenced, easiest-to-market PEMF indication. Patients understand "knee pain treatment" without needing complex explanation. They present in large numbers, accept treatment series, and refer family members with the same complaint. For the Philippines specifically, knee OA volume at physiotherapy clinics is approximately 3–4× higher than in Western Europe due to floor-sitting culture, high BMI prevalence, and agricultural occupational demands on the knee joint.

What This Means for Clinic Investors

Knee OA is the anchor indication for any PEMF clinic business case. The combination of very large evidence base (Grade A, multiple meta-analyses), high patient volume in the Philippines, clear treatment course (8–12 weeks), and repeatable maintenance revenue makes knee OA the most predictable PEMF revenue stream. Break-even is a calculation rather than a promise: monthly device cost divided by your own average revenue per session gives the number of sessions the machine must fill. We do not publish your session rate, because it is yours and it varies by market. ⚠️ And the referral argument should be framed carefully — no trial has shown that PEMF delays or avoids knee replacement, so a cost-avoidance pitch built on that claim will not survive a conversation with an orthopaedic surgeon. What is defensible is pain reduction, improved extensor strength, and a conservative option for patients who are not yet surgical candidates.